OUR PRODUCTS

MOBILE APPS

GENERAL INFO

IMTX

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Immatics (IMTX) Earnings Date & Reports

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

IMTX is expected to report earnings to fall 34.50% to -37 cents per share on November 18

Q3'25

Est.

$-0.38

Q2'25

Missed

by $0.28

Q1'25

Missed

by $0.07

Q4'24

Beat

by $0.74

Q3'24

Beat

by $0.14

The last earnings report on August 13 showed earnings per share of -57 cents, missing the estimate of -30 cents. With 973.72K shares outstanding, the current market capitalization sits at 650.34M.

View a ticker or compare two or three

Compare

IMTX

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For IMTX
(Try 14 days for Free)

Interact to see
Advertisement

A.I.Advisor

published price charts

These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMTX showed earnings on August 13, 2025. You can read more about the earnings report here.

View AI-Driven Trading

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

Paul-Ehrlich-Strasse 15

Phone

+49 707153970

Employees

343

Web

https://www.immatics.com